Alex Thompson
Stock Analyst at Stifel
(1.16)
# 3,452
Out of 4,829 analysts
34
Total ratings
46.15%
Success rate
-11.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Hold | $22 → $23 | $20.02 | +14.89% | 3 | May 2, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Hold | $23 → $5 | $5.15 | -2.91% | 2 | Mar 28, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $4.06 | +786.70% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $30.68 | +95.57% | 1 | Mar 25, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $151.46 | +36.67% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $9.54 | +413.63% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $549.27 | -8.97% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $14.10 | +282.98% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $19.61 | +124.38% | 1 | Feb 15, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Hold | $6 → $2 | $1.24 | +61.29% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $38.39 | +79.76% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.26 | -20.63% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $12.39 | +222.84% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.75 | +5,208.56% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $14.02 | +142.51% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.41 | +2,240.43% | 1 | Dec 14, 2022 |
Travere Therapeutics
May 2, 2025
Maintains: Hold
Price Target: $22 → $23
Current: $20.02
Upside: +14.89%
Third Harmonic Bio
Mar 28, 2025
Downgrades: Hold
Price Target: $23 → $5
Current: $5.15
Upside: -2.91%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $4.06
Upside: +786.70%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $30.68
Upside: +95.57%
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $151.46
Upside: +36.67%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $9.54
Upside: +413.63%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $549.27
Upside: -8.97%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $14.10
Upside: +282.98%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $19.61
Upside: +124.38%
Ventyx Biosciences
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $1.24
Upside: +61.29%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $38.39
Upside: +79.76%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.26
Upside: -20.63%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $12.39
Upside: +222.84%
Aug 9, 2023
Initiates: Buy
Price Target: $40
Current: $0.75
Upside: +5,208.56%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $14.02
Upside: +142.51%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.41
Upside: +2,240.43%